Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
DMAC Stock Summary
Top 10 Correlated ETFs
DMAC
In the News
Wall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich
The bullish sentiment in the market is leading some investors to look at risk-on assets. Bitcoin may be an option, but for investors who prefer to stay in stocks, it may be time to look for some of the analysts' favorite penny stocks.
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023
DiaMedica Therapeutics (NASDAQ: DMAC ) just reported results for the fourth quarter of 2023. DiaMedica Therapeutics reported earnings per share of -14 cents.
DiaMedica Therapeutics Inc. (DMAC) Q3 2023 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q3 2023 Earnings Call Transcript November 14, 2023 8:00 AM ET Company Participants Rick Pauls - President and CEO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Alexander Nowak - Craig-Hallum Capital Group Francois Brisebois - Oppenheimer. Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Third Quarter 2023 Conference Call.
Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year?
Here is how DiaMedica Therapeutics, Inc. (DMAC) and DermTech, Inc. (DMTK) have performed compared to their sector so far this year.
DiaMedica Therapeutics Inc. (DMAC) Q2 2023 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q2 2023 Earnings Call Transcript August 15, 2023 8:00 AM ET Company Participants Rick Pauls - President and CEO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Alex Nowak - Craig-Hallum Capital Group Dan Hultberg - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Second Quarter 2023 Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.
DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its second quarter 2023 financial results will be released after the markets close on Monday, August 14th. DiaMedica will host a live conference call on Tuesday, August 15th at 7:00 AM Central Time to provide a business update and discuss financial results. Co.
DiaMedica Therapeutics Inc. (DMAC) Q1 2023 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q1 2023 Earnings Conference Call May 16, 2023 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Alex Nowak - Craig-Hallum Daniel Hultberg - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2023 Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.
DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2023 financial results will be released after the markets close on Monday, May 15th. DiaMedica will host a live conference call on Tuesday, May 16th at 7:00 AM Central Time to provide a business update and discuss financial results. Conferenc.
DiaMedica Therapeutics Inc. (DMAC) Q4 2022 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q4 2022 Earnings Conference Call March 29, 2023 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financial Officer Kirsten Gruis - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Alexander Nowak - Craig-Hallum Capital Group Daniel Hultberg - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics ReMEDy2 Update Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.
DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its full-year 2022 financial results will be released after the markets close on Tuesday, March 28th. DiaMedica will host a live conference call on Wednesday, March 29th at 7:00 AM Central Time to provide a business update and discuss financial results.
DMAC Financial details
DMAC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.89 | -0.78 | -0.65 | -0.52 | -0.6 | |
Operating cash flow per share | -0.76 | -0.59 | -0.59 | -0.44 | -0.58 | |
Free cash flow per share | -0.76 | -0.59 | -0.59 | -0.44 | -0.58 | |
Cash per share | 0.66 | 1.75 | 2.17 | 1.27 | 1.62 | |
Book value per share | 0.64 | 1.66 | 2.12 | 1.2 | 1.57 | |
Tangible book value per share | 0.64 | 1.66 | 2.12 | 1.2 | 1.57 | |
Share holders equity per share | 0.64 | 1.66 | 2.12 | 1.2 | 1.57 | |
Interest debt per share | 0.01 | 0.01 | 0 | 0 | 0.01 | |
Market cap | 58.14M | 159M | 77.48M | 41.78M | 92.49M | |
Enterprise value | 54.44M | 151.71M | 72.83M | 37.52M | 88.35M | |
P/E ratio | -5.46 | -12.94 | -5.7 | -3.05 | -4.77 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -6.39 | -17.31 | -6.32 | -3.63 | -4.94 | |
PFCF ratio | -6.39 | -17.22 | -6.31 | -3.6 | -4.93 | |
P/B Ratio | 7.63 | 6.11 | 1.76 | 1.31 | 1.81 | |
PTB ratio | 7.63 | 6.11 | 1.76 | 1.31 | 1.81 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -5.08 | -12.16 | -5.35 | -2.68 | -4.16 | |
EV to operating cash flow | -5.98 | -16.52 | -5.94 | -3.26 | -4.72 | |
EV to free cash flow | -5.98 | -16.43 | -5.93 | -3.24 | -4.71 | |
Earnings yield | -0.18 | -0.08 | -0.18 | -0.33 | -0.21 | |
Free cash flow yield | -0.16 | -0.06 | -0.16 | -0.28 | -0.2 | |
Debt to equity | 0.02 | 0 | 0 | 0.01 | 0.01 | |
Debt to assets | 0.02 | 0 | 0 | 0.01 | 0.01 | |
Net debt to EBITDA | 0.35 | 0.58 | 0.34 | 0.3 | 0.2 | |
Current ratio | 6.7 | 13.77 | 29.82 | 15.61 | 19.27 | |
Interest coverage | 0 | 0 | 0 | 39.66 | 0 | |
Income quality | 0.85 | 0.75 | 0.9 | 0.84 | 0.97 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.01 | 0 | 0.01 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.1 | -2.24 | -0.92 | -3.24 | -0.8 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 3.56 | 5.41 | 5.59 | 3.74 | 4.58 | |
ROIC | -1.46 | -0.48 | -0.31 | -0.43 | -0.41 | |
Return on tangible assets | -1.18 | -0.44 | -0.3 | -0.4 | -0.36 | |
Graham Net | 0.59 | 1.64 | 2.11 | 1.17 | 1.54 | |
Working capital | 7.52M | 25.89M | 43.92M | 31.67M | 50.89M | |
Tangible asset value | 7.62M | 26.01M | 44.02M | 31.83M | 51.06M | |
Net current asset value | 7.4M | 25.84M | 43.91M | 31.27M | 50.57M | |
Invested capital | 0.02 | 0 | 0 | 0.01 | 0.01 | |
Average receivables | 801.5K | 581.5K | 235K | 106K | 225.5K | |
Average payables | 332.5K | 640.5K | 804K | 621.5K | 830K | |
Average inventory | 44K | 49K | 61.5K | 56.5K | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 3.16K | 19.1K | 7.74K | 10.72K | 11.27K | |
Days of inventory on hand | 1.53K | 173.81 | 1.72K | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.12 | 0.02 | 0.05 | 0.03 | 0.03 | |
Inventory turnover | 0.24 | 2.1 | 0.21 | 0 | 0 | |
ROE | -1.4 | -0.47 | -0.31 | -0.43 | -0.38 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.14 | -0.2 | -0.16 | -0.12 | -0.14 | |
Operating cash flow per share | -0.1 | -0.19 | -0.18 | -0.13 | -0.09 | |
Free cash flow per share | -0.11 | -0.19 | -0.18 | -0.13 | -0.09 | |
Cash per share | 1.27 | 1.08 | 1.48 | 1.22 | 1.39 | |
Book value per share | 1.2 | 1.02 | 2.19 | 1.47 | 1.35 | |
Tangible book value per share | 1.2 | 1.02 | 2.19 | 1.47 | 1.35 | |
Share holders equity per share | 1.2 | 1.02 | 2.19 | 1.47 | 1.35 | |
Interest debt per share | 0.01 | -0.2 | 0.02 | 0.01 | 0.01 | |
Market cap | 41.78M | 40.47M | 117.99M | 97.91M | 107.8M | |
Enterprise value | 37.52M | 38.78M | 112.59M | 96.1M | 103.66M | |
P/E ratio | -2.78 | -1.92 | -6.59 | -5.47 | -5.22 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -15.1 | -7.95 | -23.46 | -20.41 | -30.11 | |
PFCF ratio | -14.93 | -7.94 | -23.44 | -20.37 | -30.09 | |
P/B Ratio | 1.31 | 1.5 | 1.97 | 1.76 | 2.11 | |
PTB ratio | 1.31 | 1.5 | 1.97 | 1.76 | 2.11 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -9.46 | -7.03 | -23.78 | -9.32 | -17.75 | |
EV to operating cash flow | -13.57 | -7.62 | -22.38 | -20.03 | -28.96 | |
EV to free cash flow | -13.41 | -7.61 | -22.37 | -19.99 | -28.93 | |
Earnings yield | -0.09 | -0.13 | -0.04 | -0.05 | -0.05 | |
Free cash flow yield | -0.07 | -0.13 | -0.04 | -0.05 | -0.03 | |
Debt to equity | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | |
Debt to assets | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | |
Net debt to EBITDA | 1.07 | 0.31 | 1.14 | 0.18 | 0.71 | |
Current ratio | 15.61 | 10.55 | 21.19 | 22.07 | 19.27 | |
Interest coverage | 17.35 | 0.96 | 0 | 0 | 0 | |
Income quality | 0.74 | 0.97 | 1.12 | 1.07 | 0.69 | |
Dividend Yield | 0 | 0 | 0.31 | 0 | 0 | |
Payout ratio | 0 | 0 | -8.26 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -5.33 | -1 | -0.57 | -1.25 | -0.34 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 1.96 | 2.14 | 2.84 | 1.97 | 2.03 | |
ROIC | -0.12 | -0.2 | -0.08 | -0.18 | -0.11 | |
Return on tangible assets | -0.11 | -0.17 | -0.07 | -0.08 | -0.1 | |
Graham Net | 1.17 | 0.96 | 1.4 | 1.16 | 1.32 | |
Working capital | 31.67M | 26.86M | 39.29M | 45.72M | 50.89M | |
Tangible asset value | 31.83M | 27.02M | 59.74M | 55.63M | 51.06M | |
Net current asset value | 31.27M | 26.48M | 38.92M | 45.38M | 50.57M | |
Invested capital | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | |
Average receivables | 78.5K | 69.5K | 122.5K | 249K | 339.5K | |
Average payables | 799K | 1.26M | 1.32M | 859.5K | 894.5K | |
Average inventory | 4.5K | -28.5K | -122.5K | -94K | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 11.01K | 29.02 | 16.25 | 15.06 | 10.42K | |
Days of inventory on hand | 0 | -0.93 | -3.57 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.01 | 3.1 | 5.54 | 5.98 | 0.01 | |
Inventory turnover | 0 | -96.86 | -25.22 | 0 | 0 | |
ROE | -0.12 | -0.2 | -0.07 | -0.08 | -0.1 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
DMAC Frequently Asked Questions
What is DiaMedica Therapeutics Inc. stock symbol ?
DiaMedica Therapeutics Inc. is a US stock , located in Minneapolis of Mn and trading under the symbol DMAC
What is DiaMedica Therapeutics Inc. stock quote today ?
DiaMedica Therapeutics Inc. stock price is $2.78 today.
Is DiaMedica Therapeutics Inc. stock public?
Yes, DiaMedica Therapeutics Inc. is a publicly traded company.